Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Pharmaceutic, chemical company Monsanto was found liable by a Washington jury for $100 million on Tuesday, according to ...

2025 Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

Bayer (BAYGn.DE), opens new tab will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in ...

(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...